ABATA

Abata was launched in 2021 by Third Rock Ventures with a $95 million Series A financing and brings together industry experts and deeply engaged pioneers in regulatory T cell (Treg) biology, T cell receptor (TCR) and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers to advance the development of Treg cell therapies for serious autoimmune and inflammatory diseases... Together, we are bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis - a state of harmony - and promote repair in the affected tissues... We are industry experts and scientific pioneers working together to bring an entirely new approach to the treatment of autoimmune disease.

Primary location: Watertown United States